GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Myriad Genetics Inc (NAS:MYGN) » Definitions » Pre-Tax Income

MYGN (Myriad Genetics) Pre-Tax Income : $-116.6 Mil (TTM As of Sep. 2024)


View and export this data going back to 1995. Start your Free Trial

What is Myriad Genetics Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Myriad Genetics's pretax income for the three months ended in Sep. 2024 was $-21.2 Mil. Its pretax income for the trailing twelve months (TTM) ended in Sep. 2024 was $-116.6 Mil. Myriad Genetics's pretax margin was -9.94%.

During the past 13 years, Myriad Genetics's highest Pretax Margin was 35.70%. The lowest was -34.97%. And the median was 4.97%.


Myriad Genetics Pre-Tax Income Historical Data

The historical data trend for Myriad Genetics's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myriad Genetics Pre-Tax Income Chart

Myriad Genetics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Dec21 Dec22 Dec23
Pre-Tax Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -223.30 -57.10 -140.60 -262.20

Myriad Genetics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Pre-Tax Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -61.20 -32.30 -25.90 -37.20 -21.20

Competitive Comparison of Myriad Genetics's Pre-Tax Income

For the Diagnostics & Research subindustry, Myriad Genetics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Myriad Genetics's Pre-Tax Income Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Myriad Genetics's Pre-Tax Income falls into.



Myriad Genetics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Myriad Genetics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-144.6+-117.2+-2.9+2.5+0
=-262.2

Myriad Genetics's Pretax Income for the quarter that ended in Sep. 2024 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-17.8+-3+-0.8+0.4+3.5527136788005E-15
=-21.2

Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-116.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Myriad Genetics  (NAS:MYGN) Pre-Tax Income Explanation

Myriad Genetics's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as

Pretax Margin=Pretax Income/Revenue
=-21.2/213.3
=-9.94%

During the past 13 years, Myriad Genetics's highest Pretax Margin was 35.70%. The lowest was -34.97%. And the median was 4.97%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Myriad Genetics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Myriad Genetics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Myriad Genetics Business Description

Traded in Other Exchanges
Address
320 Wakara Way, Salt Lake City, UT, USA, 84108
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
Executives
Paul J Diaz director, officer: President and CEO 680 SOUTH FOURTH STREET, LOUISVILLE KY 40202
Dale Muzzey officer: Chief Scientific Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Heinrich Dreismann director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Reitan Colleen F director 300 THIRD STREET, CAMBRIDGE MA 02142
Margaret Ancona officer: SVP, Chief of Staff 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Rashmi Kumar director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Lee Nisley Newcomer director 264 BUSHAWAY ROAD, WAYZATA MN 55391-1901
Richard Bryan Riggsbee officer: Chief Financial Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Nicole Lambert officer: Chief Operating Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Pamela Wong officer: Chief Legal Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Shereen Solaiman officer: Chief People Officer 320 WAKARA WAY, SALT LAKE CITY UT 84108
Paul Bisaro director
Kevin Richard Haas officer: Chief Technology Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Natalie Munk officer: Chief Accounting Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116